Clinical Trials Logo

Myeloproliferative Disorders clinical trials

View clinical trials related to Myeloproliferative Disorders.

Filter by:

NCT ID: NCT00075816 Completed - Leukemia Clinical Trials

Peripheral Blood Stem Cell Transplant vs Bone Marrow Transplant in Individuals With Hematologic Cancers (BMT CTN 0201)

Start date: January 2004
Phase: Phase 3
Study type: Interventional

The study is designed as a Phase III, randomized, open label, multicenter, prospective, comparative trial of granulocyte colony stimulating factor (G-CSF)-mobilized peripheral blood stem cells (PBSC) versus marrow from unrelated donors for transplantation in patients with hematologic malignancies. Recipients will be stratified by transplant center and disease risk and will be randomized to either the PBSC or marrow arm in a 1:1 ratio.

NCT ID: NCT00072475 Completed - Leukemia Clinical Trials

Vatalanib in Treating Patients With Primary or Secondary Myelodysplastic Syndromes

Start date: December 2003
Phase: Phase 2
Study type: Interventional

RATIONALE: Vatalanib may be effective in preventing the development of leukemia in patients who have myelodysplastic syndromes. PURPOSE: This phase II trial is studying vatalanib to see how well it works in treating patients with primary or secondary myelodysplastic syndromes.

NCT ID: NCT00068523 Completed - Lymphoma Clinical Trials

Ultraviolet-B Light Therapy and Allogeneic Stem Cell Transplantation in Treating Patients With Hematologic Malignancies

Start date: June 2003
Phase: N/A
Study type: Interventional

RATIONALE: Peripheral stem cell transplantation may be able to replace immune cells that were destroyed by chemotherapy. Sometimes the transplanted cells from a donor are rejected by the body's normal cells. Ultraviolet-B light therapy given before and after allogeneic stem cell transplantation may help prevent this from happening. PURPOSE: Clinical trial to study the effectiveness of combining ultraviolet-B light therapy with allogeneic stem cell transplantation in treating patients who have hematologic malignancies.

NCT ID: NCT00068276 Completed - Leukemia Clinical Trials

Cholecalciferol in Treating Patients With Myelodysplastic Syndrome

Start date: July 2003
Phase: Phase 2
Study type: Interventional

RATIONALE: Cholecalciferol (vitamin D) may improve quality of life by increasing blood counts, decreasing fatigue, and improving other symptoms of myelodysplastic syndrome. PURPOSE: This phase II trial is studying how well cholecalciferol works in treating patients with myelodysplastic syndrome.

NCT ID: NCT00066599 Completed - Lymphoma Clinical Trials

Voriconazole in Preventing Fungal Infections in Children With Neutropenia After Chemotherapy

Start date: June 2003
Phase: Phase 2
Study type: Interventional

RATIONALE: Voriconazole may be effective in preventing systemic fungal infections following chemotherapy. PURPOSE: Phase II trial to study the effectiveness of voriconazole in preventing systemic fungal infections in children who have neutropenia after receiving chemotherapy for leukemia, lymphoma, or aplastic anemia or in preparation for bone marrow or stem cell transplantation.

NCT ID: NCT00066248 Completed - Lymphoma Clinical Trials

Cyproheptadine and Megestrol in Preventing Weight Loss in Children With Cachexia Caused By Cancer or Cancer Treatment

Start date: June 2003
Phase: Phase 2
Study type: Interventional

RATIONALE: Cyproheptadine and megestrol may improve appetite and help prevent weight loss in children with cancer. PURPOSE: This phase II trial is studying how well cyproheptadine and megestrol work in improving appetite and preventing weight loss in children with cachexia caused by cancer or cancer treatment.

NCT ID: NCT00064311 Completed - Breast Cancer Clinical Trials

Ravuconazole in Preventing Fungal Infections in Patients Undergoing Allogeneic Stem Cell Transplantation

Start date: June 2003
Phase: Phase 1/Phase 2
Study type: Interventional

RATIONALE: Antifungals such as ravuconazole may be effective in preventing fungal infections in patients undergoing chemotherapy and stem cell transplantation. PURPOSE: Phase I/II trial to study the effectiveness of ravuconazole in preventing fungal infections in patients undergoing allogeneic stem cell transplantation.

NCT ID: NCT00064090 Completed - Leukemia Clinical Trials

3-AP and Cytarabine in Treating Patients With Hematologic Cancer

Start date: March 2003
Phase: Phase 1
Study type: Interventional

RATIONALE: Drugs used in chemotherapy such as cytarabine use different ways to stop cancer cells from dividing so they stop growing or die. 3-AP may stop the growth of cancer cells by blocking the enzymes necessary for cancer cell growth and may help cytarabine kill more cancer cells by making them more sensitive to the drug. PURPOSE: Phase I trial to study the effectiveness of combining cytarabine with 3-AP in treating patients who have relapsed or refractory hematologic cancer.

NCT ID: NCT00062140 Completed - Lymphoma Clinical Trials

Total-Body Irradiation, Cyclophosphamide, and Stem Cell Transplantation in Treating Patients With Hematologic Cancer

Start date: April 2003
Phase: Phase 1
Study type: Interventional

RATIONALE: Adjusting the dose of drugs used in chemotherapy such as cyclophosphamide may decrease side effects while stopping cancer cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage cancer cells. Stem cell transplantation may be able to replace immune cells that were destroyed by chemotherapy and radiation therapy used to kill cancer cells. PURPOSE: Phase I trial to study the effect on the body of dose-adjusted cyclophosphamide combined with total-body irradiation and donor stem cell transplantation in treating patients who have hematologic cancer.

NCT ID: NCT00061581 Completed - Clinical trials for Myelodysplastic Syndromes

Experimental Bone Marrow Transplant Protocol

Start date: May 19, 2003
Phase: Phase 2
Study type: Interventional

Bone marrow transplantation (BMT) is a risky procedure. If doctors could reduce the complications, BMT would be safer to use for a wider range of conditions. The purposes of this study are - to prevent graft rejection by increasing the amount of immunosuppression and by giving some lymphocytes from the donor before transplant; - to prevent graft-versus-host disease (GVHD) by transplanting T-cell depleted stem cells; - to improve the immune effect against residual leukemia by the add-back of donor lymphocytes before transplant and six or more weeks after transplant. Beyond the standard transplant protocol, study participants will undergo additional procedures. First, along with total body irradiation, patients will receive two drugs (a high dose of cyclophosphamide and fludarabine) to suppress immunity and prevent rejection of the transplant. Second, four days before the transplant, patients will be given donor lymphocytes that have been irradiated to make them incapable of causing GVHD. On the day of the transplant, patients will receive an infusion of T-cell depleted bone marrow stem cells. Finally, patients will receive two doses of add-back donor T-cells (45 and 100 days post transplant) and the immunosuppressive drug cyclosporine starting on day 44 until about six months after transplant. Study participants must be between the ages of 10 and 56 and have a family member who is a suitable stem cell donor match.